CALL US ( 949) 515 4673
Precision Medicine in oncology

Publications and presentations

P u b l i c a t i o n s


___________________________________________________________________________________
 

1. M.A Nezami,M.D., Mirshemirani, M., M D

 “Retrospective study of 50 Hospitalized children with Nephroblastoma/ Wilm’s Tumor”

Clinical research, medical dissertation, April 1996



2. Davidson, G.C., Collins, L., Nezami, M.A. & Dequattro, V.L.

“Psychological correlates of heart’s structural variation.”

Poster presented at the society of behavioral science meeting, San Diego, California 1993

 
3. Nezami E., Davison, GC, Nezami, M.A. & Collins L.

“Hostility in relation to cardiovascular reactivity”

University of Southern California, Paper published in International Journal of Psychology, and presented in 26th international congress of psychology, Montreal, Canada, p. 127, 1996

 
4. Jadvar H, Xu A, Tumeh P, Pollock J, Nezami M.A., Conti PS

 " Surveillance and management of  lymphoma with serial FDG PET-CT",

Proc RSNA 91st Scientific Assembly & Ann Meeting, Chicago, IL, p. 673; 2005

http://archive.rsna.org/2005/4407297.html

 
5.  M. A. Nezami, M.D, Victoria Kubal MS, BCBA, John Monteleone M.D., MPH Davin Young Clarke  M.A., “Effects of Exercise Prescription and Nutrition Counseling on Patients at Risk for Cardiovascular Disease”Invited presenter, 3rd annual colloquium

University of California, San Francisco, (UCSF), 2007


6. J. Monteleone, MD, MPH, M.A. Nezami M.D., Mimi-Mott Smith FNP-MPH

“Changing Behavior using personalized exercise and nutrition prescriptions for patients at cardiovascular risk”

Society of Teachers in Family Medicine (STFM), 16th annual meeting, published STFM 16th annual journal, p 63, Chicago, 2007

 
7. M. Nezami, MD

” Improved symptoms of multiple sclerosis in response to nutritional therapy: an integrative approach to neurodegenerative disorders, a case report”

Integrative Medicine, A Clinician’s Journal ( IMCJ), Sept, 2011

 
8. M. Nezami MD

Tumor board presentation "Breast cancer complete remission using combination therapy, chemotherapy with epigenetic treatments, A case report" March, 2012, CRMC, Clovis, California

 
9. M. Nezami MD

 MultiTargeted Epigenetic therapies, MTET

Invited presenter and candidate for partnership opportunities

Lymphoma and Leukemia Society (LLS), San Francisco, 2012



10. M.Nezami MD, S.Hager DO, D. Stobbe MD,

Multitargeted Epigenetic Therapy ( MTET) and it's rationale in an integrative approach

Institute for Research ( IRB) in Bio medicine, Barcelona International Conference on Epigenetics and Cancer, Barcelona, Spain, November, 2013


11. M.Nezami MD, S.Hager DO, D. Stobbe MD

Multitargeted Epigenetic Therapy ( MTET)

Molecular Med Tri-conference,( ex, human genome project and sequencing), February 10-12, 2014, San Francisco, CA


12. M.Nezami MD, S Hager, Do

"Surrogate markers of survival , a case review for an antiangiogenic therapy in cancer"

Pancreatic Cancer Innovations in research and treatment

American Association for Cancer Research ( AARC), May 18-21, 2014 New Orleans, Louisiana


13. M.Nezami MD, S Hager, Do, A. Gouldsimon MD

"Surrogate Markers for survival, a case review for an antiangiogenic therapy in cancer"

World Pharmaceutical Congress, Trackling Translational Challenges, May 21-23, 2014, Boston, Massachusetts


14. M.Nezami MD, Steve Hager DO, A. Gouldsimon MD

"Surrogate Markers of survival, a case review for an antiangiogenic therapy in cancer"

World Molecular Imaging Society and World Molecular Imaging Congress( WMIC)

Korea, September 2014


15. LEANNA J. STANDISH, LISE N. ALSCHULER, MORGAN WEAVER AND M. NEZAMI MD

Weil's Integrative Oncology Textbook, second edition,

Botanical and Mycological Medicine in Integrative Oncology

Integrative Oncology, Donald Abrams, Andrew Weil, Sep 2014


16. M.Nezami MD, Aron Gould Simon MD,

" Biological translational tools to predict clinical outcome in advanced cancer”

Molecular Med Tri-cone 2015, San Francisco, February 2015( human genome project and sequencing)


17. M. Nezami MD, J. Garner, Aron Gouldsimon, MD,

"Epigenetic regulation of angiogenesis", A review of 100 cases of advanced cancer"

Translational epigenetics,  Festival of Genomics, Boston, June 23, 2015


18. M. Nezami MD, Daniel Stobe MD, Aron Gouldsimon, MD

"Translational epigenetics in lung cancer, A case review of multitargeted epigenetic therapy ( MTET)",

16th annual international lung cancer congress, Huntington Beach, CA July, 2015


19. Nezami MA, Gouldsimon A

" Heterogenous Approach for Heterogenous disease, Heterogeneity in cancer genomics and epigenetic approach", Cancer Science, vol 1,1, August 2015

 
20. M.Nezami MD, " Epigenetic regulation of hypoxia, Genomic Bioinformatics",

Europe Society of Bio Banking ( ESBB), London, Oct 1st, 2015


21. M. Nezami MD

"Biological interventions to interfere microenvironmental seduction by tumor cells"

Symposia on Cancer Research, Emerging concepts in host response to cancer, MD Anderson Cancer center, Houston, TX, October 8-9, 2015

 
22. M.Nezami MD, Steve Hager DO

" Prognostic surrogate makers for survival in pancreatic cancer, a case series for a novel antiangiogenic therapy( Multitargeted epigenetic therapy( MTET) 

French Association for Pancreatic Cancer Research ( AFRCP), Pancreatic Cancer Symposium, Marcielle, France, October 28-30


23. M. Nezami MD, Steve Hager DO, Richard Lanman MD

" Impact of Multitargeted Epigenetic therapy ( MTET), a series of 100 consecutive advanced solid tumor cancers"

AACR- NCI EORTC Molecular Targets and Cancer Therapeutics Conference, Nov 5-9, 2015, Boston, Massachusetts

 
24. M. Nezami MD, Steve Hager DO

“Heterogenous approach for heterogenous disease, heterogeneity in cancer genomics and epigenetic approach”

AACR- NCI EORTC Molecular Targets and Cancer Therapeutics Conference, Nov 5-9, 2015, Boston, Massachusetts


25. M.Nezami MD, Aron Gouldsimon MD

" Application of multitargeted Epigenetic therapy and review of case series in recurrent advanced Non small Cell Lung Cancer, Heterogenous approach for heterogenous disease, Heterogeneity in cancer genomics and epigenetic approach"

Cancer Science, open access, scient online, Vol. 1,  http://scientonline.org/open-access/heterogenous-approach-for-heterogenous-disease-heterogeneity-in-cancer-genomics-and-epigenetic-approach.pdf


26. M. Nezami MD, Jessica garner PA, Megan Elam

" Epigenetic therapies, Immune therapies and Anti angiogenic therapies, The Triad of Oncology"

Angiogenesis, The cause or effect?"

Journal of Precision Medicine, November 2015, Page 43

 
27. M. Nezami MD, Steve Hager DO, Jessica Garner PA,

" Epigenetic Regulation of heterogeneity in solid tumors, A case series for a novel epigenetic therapy"

Society of Integrative Oncology ( SIO), Integrative Innovations, Nov 12-14, 2015, Boston, Massachusetts


28. M.Nezami MD, Daniel Stobe MD, Aron Gould Simon MD

"Prognostic surrogate markers for survival, a case series for a novel antiangiogenic therapy( Multitargeted Epigenetic Therapies/ MTET)" Abstract 73

Society of Integrative Oncology( SIO), November 14-16, 2015, Boston, Massachusetts


29. M. Nezami MD

" Epigenetic regulation of hypoxia and heterogeneity in cancer"8th Euro Global Summit on Cancer Therapy, November 3th-5th, 2015, Valencia, Spain


30. M. Nezami MD

" Multitargeted Epigenetic therapy and it's application in a case series of Gastric Cancer"

2nd International Gastrointestinal Cancer Congress ( IGCC), October 14-16th, Shahid Beheshti University, Comprehensive Cancer Center, Tehran, Iran


31. Nezami M, Hager S, Garner, J

" Epidermomesenchymal (Transition( EMT) and Anti EMT Strategies in Cancer", Journal of Cancer therapy  (JCT), Vol 6, No 11, November 2015, Paper ID: 890225


32. M.Nezami MD

"Epigenetic regulation of Hypoxia, a case series for multitargeted epigenetic therapy"4th Cancer Epigenetic Conference, Global Technology Community ( GTC), November 16-17th, San Francisco, CA

33. M.Nezami MD, A Gouldsimon, D. Stobe

" Epigenetic regulation of Hypoxia and heterogeneity", ESMO Journal , Annals of Oncology, Submission ID:#495ESMO

https://doi.org/10.1093/annonc/mdv533.14

Asia 2015 Congress, December 18-21, Singapore


34. M. Nezami MD

“Chemoprevention and epigenetic multitargeted approach” , 2016 Cancer survivorship Symposium: Advancing Care and Research, Abstract Submission ID:156951 (Abstract Number for Online Publication: e297)

 
35.M. Nezami MD, Aroun Gouldsimon MD, Jessica Garner

 "Correlation of an EX VIVO model with clinical application of an epigenetic modifier, inhibiting tumor growth and metastasis, in resistant cholangiocarcinoma - A case study" ,

 Journal of Cancer Therapy, Vol 7, No.1, Jan 2016

 
36. M.Nezami MD

"Chemoprevention and Epigenetic Multitargeted Approach"

Dana-Farber Cancer Institute, Cancer Survivorship Symposium: Advancing Care and Research

Journal of Clinical Oncology 34, 2016 ( Suppl 3S, Abstr e297)

37. M.Nezami MD

"Multitargeted Epigenetic therapy and it's application in a case series of advanced Gastric Cancer"

The 2nd International Conference on Oncology and Therapy (COT 2016)

March 2 - 4, 2016 in Beijing, China.


38. M. Nezami MD, Aroun GouldSimon MD

"Biological interventions to interfere microenvironmental seduction by tumor cells, a breakthrough strategy in clinical oncology to inhibit angiogenesis and metastasis"

Molecular Medicine TRI-CON 2016 , March 6 -11, 2016, San Francisco, CA

 
39.M.A.Nezami MD, Steve Hager Do, Jessica Garner PA

" Preliminary Findings on Multi-Targeted Epigenetic Therapy in Modifying Telomerase Activity"

Journal of Cancer Science( Scient Open Access Journal), March 16, 2016


40. M.Nezami MD

" Invitro and invivo proof of concept for an effective antineoplastic combination of novel anti HIF therapy in pancreatic cancer"

American Association for Cancer Research ( AACR), Pancreatic Cancer, Advances in Science and Clinical Care

May 12-15, Orlando, Florida

 
41. M.Nezami MD, S. Hager, DO J. Garner

"The Role of Telomeres in Cancer Development and Progression, and the Double Edge Sword Effect with Tamoxifen"

Biology and Medicine ( Biol Med 2016, 8:3)


42. M. Nezami MD, Steven Hager DO, Jessica Garner

"Preliminary Findings on Multi-Targeted Epigenetic Therapy (MTET) in Modifying Telomerase Activity"

- Cancer Science; Open Access, Scient access, published March, 2016


43. M. Nezami MD, Steven Hager DO, Jessica Garner

"Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi-Targeted Epigenetic Therapy (MTET)" - Journal of Cancer Therapy, Vol 7, No 4, Apr 13, 2016, DOI: 10.4236/jct.2016.74027

 
44. M. Nezami MD

Peer review expert, British Journal of Medicine and Medical Research

" Tumor markers in head and neck neoplasm: an overview"

Published: Ms_BjMMR_24998

 
45. Peer review expert, Science Domain International, Asian Journal of Medicine and Health

" Superficial Angiomyxoma of right gluteal region- A rare case report"

SDI/Q/PR/AJMAH/29142


46. Peer review expert, Science Domain International,Journal of Advances in Medical and Pharmaceutical Sciences

" Effect of Hypoxia-inducible factor-1 and 2 on tumor growth"

Ms_JAMPS_29407


47. Peer review expert, Science Domain, Journal of cancer and tumor international," The interest of serum alkaline phosphatase in the confirmation of diagnosis for tumors in children and adolescents" Ms_JCTI_2993

 
48. Peer Review Expert, Biology and Medicine, Medical Sciences 17-134

"Association between serum Trans fatty acids concentrations and leucocyte telomere length in US adults" Feb, 2017


49. Peer review expert, Biology and Medicine, Medical Sciences 17-285

" Long Non-coding RNA Biomarker for Human Laryngeal Squamous Cell Carcinoma Prognosis", March 2017


50. M.Nezami MD

"Epigenetic regulation of hypoxia: Modifying metastasis by regulating epigenome- A Case review of multi targeted epigenetic therapy (MTET) and its application in Stage IV Renal Cell Carcinoma

International Conference on Oncology and Radiology( ICOR), Dubai, UAE

October 27-29, 2016

 
51. M.Nezami MD

( Key note speaker and organizing committee member)

"Epigenetic therapies and the use of multitargeted approach, a new concept in cancer therapeutics"

International conference on Radiation oncology and anti cancer therapy

Dubai, UAE, Nov 21-22, 2016


52. M.Nezami MD

" Biological interventions to interfere microenvironmental and endocrine machinery in cancer" Application of endocrine manipulation in advanced cancer

13th Global Summit on Cancer therapy, November 21-23, 2016, Dubai, UAE

Journal of Cancer Science and Therapy


53. M.Nezami MD, Jessica Garner “ Role of antiangiogenic therapy in prevention of cancer recurrence in hormonal positive breast cancer, A secondary prevention strategy and method of therapy”, JCT, , 6.2017, 8/546/552


54. M. Nezami MD, "Multi targeted Epigenetic therapy and hypoxia response elements, A turning point in radiation oncology"  
2nd International conference on Nuclear Medicine and Radiation Therapy, July 27-28, 2017, Rome, Italy

55. M.Nezami MD
" Biological modulation of PARP inhibition in triple negative breast cancer: A case report of combinational approach implementing histone deacetylase inhibition with PARP inhibition in advanced breast cancer", 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, October 26-30, 2017 in Philadelphia, Pennsylvania

56. M.Nezami MD, “ From Innovation to commercialization”, Biotechnology Show Case, san Francisco, Januray 7-10, 2018

57. M. Nezami MD“Molecular profiling in cancer and correlation of liquid biopsies with clinical outcome”Invited presenter, Bastyr University, March 2018

58. Julie Taguchi, Christopher Duma, M.Nezami“A Novel Combined Approach for Metastatic Breast Cancer with Dural and Leptomeningeal Disease with an Impressive Clinical Outcome: A Case Study”, Marhc 2018, JCT

59. Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer

Aditya Bardia1, Thereasa A. Rich2, Victoria M. Raymond2, Stephen R. Fairclough2, Oliver Sartor3, Michael B. Lilly4, Mohammad Amin Nezami5, Sandip Patel6, Benedito A. Carneiro7, Grace Wang8, Alice C. Fan9, Adam M. Brufsky10, Barbara A. Parker6, Benjamin B. Bridges11, Neeraj Agarwal12, Benjamin L. Maughan12, Richard B. Lanman2, Massimo Cristofanilli13.

ASCO 2018

60. M.Nezami MD, Christopher Duma MD "Proof of Concept in a Case Study of Glioblastoma Multiforme Successfully Treated with IV Quercetin in Combination with Leading Edge Gamma Knife and Standard Treatments", Journal of Cancer Therapy ( JCT), Volume 9, No. 6, June 2018, 10.4236/jct.2018.96043  

61. 25. M.Nezami , Steve Hager, Julie Taguchi, "Biological Modulation of PARP Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (MTET) with PARP Inhibition, in Advanced Breast Cancer: A Case Study". JCT, Sept 2018,  ISSN 2151-1942

62. M.Nezami, Steve Hager " Evidence Based Medicine, in Precision Oncology, JCT, Sept 2018, Vol9, Number 9, 679-805, Sept 2018, Journal of Cancer Therapy, http://www.scirp.org/journal/

63.. M.Nezami MD, Stave Hager DO, Aron Gouldsimon MD, "Induction of cell differentiation and genomic stability in cancer, by an “multi epimutation-targeted therapy”, or MTET", Open Access Text ( OAT), September 2018, ISSN: 2516-5283  https://www.oatext.com/pdf/CMR-1-129.pdf

64. M.Nezami , A GouldSimon, Jessica Garner," Preliminary findings on a sequential and combined targeted epigenetic therapy through MAPK and MEK inhibition: A case study of advanced neuroendocrine malignancy, Open Access Text ( OAT), September 2018, ISSN: 2516-5283

65. M.Nezami MD, S Hager DO, Clinical implications of epidermal growth factor receptor (EGFR) epigenetic modification in lung cancer, proof of concept for dual multitargeted epigenetic therapy (MTET) in combination with EGFR inhibitors, January 2018, DOI: 10.15761/CMR.1000132

https://www.researchgate.net/publication/328453409


66. Mohammad Nezami, Steve Hager, Journal of Cancer Therapy, 2018, 9,
Dual Epidermal Growth Factor Inhibition and Multi Targeted Epigenetic Therapy (MTET)

http://www.scirp.org/journal/jct

67. M.Nezami MD, Bio show case, San Francisco, Jan 7th, Multitargeted Epigenetic therapy, Updates

https://ebdgroup.knect365.com/biotech-showcase

68. M.Nezami MD, Sequential and dual Inhibition of Pleiotropic targets in cancer - A novel strategy to sensitize tumor cells to targeted therapies and overcome resistance, Journal of Cancer Therapy, 2019, 10, 166-177 http://www.scirp.org/journal/jc

69. Mohammad A. Nezami, Christian Klowsowski, Steven Jeffrey Hager; Research Cancer Institutes of America, Sahel Oncology, Newport Beach, CA; Guardant health, Genomic Specialist, Medical Affairs, Redwood City, CA; California Cancer Associates for Research and Excellence, Fresno, CA
“ Predictive molecular tumor response through circulating DNA (cDNA) measurements and correlation with established prognostic markers in a series of solid tumors treated with multitargeted epigenetic therapy (MTET)"
J Clin Oncol 37, 2019 (suppl; abstr e13015)
ASCO 2019, http://abstracts.asco.org/239/AbstView_239_259525.html

70. M.Nezami MD, "Multi-targeted epigenetic therapy of Glioblastoma Multiforme( GBM) stem cells and the role of epithelial mesenchymal transition", Society for brain mapping and therapeutics( SBM), sponsored by Cedars-Sinai Medical Center, City of Hope, LLU and SBM, March, 15, 2019, https://www.worldbrainmapping.org/

71. M.Nezami, "Evidence Based Medicine, in Precision Oncology Application of epigenetic therapies in an integrative approach to advanced solid tumors, a successful case for biomarker approach in cancer therapeutics",  UCI Applied Innovation ,Pathways to Cures Translational Science Research Day, May 1st, 2019

72. M.Nezami MD, “Questionable alternative therapies for cancer,  The devil is in the detail”, Oat Text DOI: 10.15761/CMR.1000142, 2/2/2019

73. M.Nezami MD, "Precision oncology and therapeutics in pancreatic cancer, implementing epigenetic approach " Winnovation and Global Depolyment of precision oncology", WIN Symposium 2019 Paris, France, June 23,24, 2019


74. Identification of actionable fusions as an anti-EGFR resistance mechanism using a circulating tumor DNA assay, ASCO 2019, JAMA 2019

Katherine Clifton, MD1+, Thereasa A. Rich2+, Christine Parseghian, MD1, Victoria M. Raymond2, Arvind Dasari, MD1, Allan Andresson Lima Pereira, MD1, Jason Willis, MD1, Jonathan M. Loree, MD3, Todd Bauer, MD4 , Young Chae, MD5, Gary Sherrill, MD6, Paul Fanta, MD7, Axel Grothey, MD8, Andrew Hendifar, MD9, David Henry, MD10, Daruka Mahadevan, MD11, Mohammad Amin Nezami, MD12, Benjamin Tan, MD13,  Zev Wainberg, MD14, Richard Lanman, MD2, Scott Kopetz, MD1, Van Morris, MD1*

1The University of Texas-MD Anderson Cancer Center, Houston TX, 2GuardantHealth Inc., Redwood City, CA, 3BC Cancer, Vancouver, CA, 4Tennessee Oncology, Nashville, TN, 5Northwestern University Feinberg School of Medicine, Chicago, IL, 6Cone Health Cancer Center, Greensboro, NC, 7University of San Diego Moores Cancer Center, La Jolla, CA, 8The University of Tennessee West Cancer Center, Memphis, TN, 9Cedars-Sinai Medical Center, Los Angeles, CA, 10University of Pennsylvania, Philadelphia, PA, 11The University of Arizona Cancer Center, Tucson, AZ, 12Pacific Medical Center of Hope, Fresno, CA, 13Washington University School of Medicine, St. Louis, MO, 14University of California Los Angeles, Los Angeles, CA